Protection Against SARS-CoV-2 Beta Variant in Mrna-1273 Boosted Nonhuman Primates
Kizzmekia S. Corbett,Matthew Gagne,Danielle A. Wagner,Sarah O’ Connell,Sandeep R. Narpala,Dillon R. Flebbe,Shayne F. Andrew,Rachel L. Davis,Barbara Flynn,Timothy S. Johnston,Christopher Stringham,Lilin Lai,Daniel Valentin,Alex Van Ry,Zackery Flinchbaugh,Anne P. Werner,Juan I. Moliva,Manjari Sriparna,Sijy O’Dell,Stephen D. Schmidt,Courtney Tucker,Angela Choi,Matthew Koch,Kevin W. Bock,Mahnaz Minai,Bianca M. Nagata,Gabriela S. Alvarado,Amy R. Henry,Farida Laboune,Chaim A. Schramm,Yi Zhang,Lingshu Wang,Misook Choe,Seyhan Boyoglu-Barnum,Wei Shi,Evan Lamb,Saule T. Nurmukhambetova,Samantha J. Provost,Mitzi M. Donaldson,Josue Marquez,John-Paul M. Todd,Anthony Cook,Alan Dodson,Andrew Pekosz,Eli Boritz,Aurélie Ploquin,Nicole Doria-Rose,Laurent Pessaint,Hanne Andersen,Kathryn E. Foulds,John Misasi,Kai Wu,Andrea Carfi,Martha C. Nason,John Mascola,Ian N. Moore,Darin K. Edwards,Mark G. Lewis,Mehul S. Suthar,Mario Roederer,Adrian McDermott,Daniel C. Douek,Nancy J. Sullivan,Barney S. Graham,Robert A. Seder
DOI: https://doi.org/10.1101/2021.08.11.456015
2021-01-01
Abstract:Neutralizing antibody responses gradually wane after vaccination with mRNA-1273 against several variants of concern (VOC), and additional boost vaccinations may be required to sustain immunity and protection. Here, we evaluated the immune responses in nonhuman primates that received 100 µg of mRNA-1273 vaccine at 0 and 4 weeks and were boosted at week 29 with mRNA-1273 (homologous) or mRNA-1273.β (heterologous), which encompasses the spike sequence of the B.1.351 (beta or β) variant. Reciprocal ID50 pseudovirus neutralizing antibody geometric mean titers (GMT) against live SARS-CoV-2 D614G and the β variant, were 4700 and 765, respectively, at week 6, the peak of primary response, and 644 and 553, respectively, at a 5-month post-vaccination memory time point. Two weeks following homologous or heterologous boost β-specific reciprocal ID50 GMT were 5000 and 3000, respectively. At week 38, animals were challenged in the upper and lower airway with the β variant. Two days post-challenge, viral replication was low to undetectable in both BAL and nasal swabs in most of the boosted animals. These data show that boosting with the homologous mRNA-1273 vaccine six months after primary immunization provides up to a 20-fold increase in neutralizing antibody responses across all VOC, which may be required to sustain high-level protection against severe disease, especially for at-risk populations.One-sentence summary mRNA-1273 boosted nonhuman primates have increased immune responses and are protected against SARS-CoV-2 beta infection.### Competing Interest StatementK.S.C. and B.S.G. are inventors on U.S. Patent No. 10,960,070 B2 and International Patent Application No. WO/2018/081318 entitled Prefusion Coronavirus Spike Proteins and Their Use. K.S.C. and B.S.G. are inventors on US Patent Application No. 62/972,886 entitled 2019-nCoV Vaccine. J.M., L.W., C.A.S., J.R.M, D.D, N.J.S., A.R.H., W.S., Y.Z. and M.R. are inventors on US patent application No. 63/147,419 entitled Antibodies Targeting the Spike Protein of Coronaviruses. D.V., A.V.R., Z.F., A.C., L.P., H.A., and M.G.L. are employees of Bioqual. K.S.C, B.S.G, L.W., W.S., and Y.Z. are inventors on multiple US Patent Applications entitled Anti-Coronavirus Antibodies and Methods of Use. A.C., M.K., A.C., and D.K.E. are employees of Moderna. M.S.S. serves on the scientific board of advisors for Moderna.